Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CFO Sells $35,580.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $23.72, for a total transaction of $35,580.00. Following the transaction, the chief financial officer now directly owns 964 shares in the company, valued at $22,866.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

AnaptysBio Stock Performance

ANAB opened at $23.91 on Monday. The firm has a market cap of $653.22 million, a P/E ratio of -3.89 and a beta of -0.32. The business has a 50 day moving average price of $22.88 and a 200 day moving average price of $21.66. AnaptysBio, Inc. has a twelve month low of $13.36 and a twelve month high of $27.50.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. The business had revenue of $9.01 million during the quarter, compared to analysts’ expectations of $3.28 million. As a group, analysts anticipate that AnaptysBio, Inc. will post -6.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on ANAB shares. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of AnaptysBio in a research report on Friday, May 10th. Stifel Nicolaus began coverage on AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price target for the company. BTIG Research began coverage on AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 price target for the company. Finally, SVB Leerink began coverage on shares of AnaptysBio in a research report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.38.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio during the 1st quarter worth about $38,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after buying an additional 2,390 shares during the last quarter. Quest Partners LLC acquired a new position in shares of AnaptysBio during the fourth quarter worth approximately $119,000. SG Americas Securities LLC acquired a new position in shares of AnaptysBio during the fourth quarter worth approximately $126,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 3,381 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.